Proton successfully treats pediatric patients with rhabdomyosarcoma

Share This Post

In September 2015, a child patient with rhabdomyosarcoma in Guangdong, China successfully completed proton radiotherapy at the Proton Center of the Eastern Hospital of the National Cancer Center in Japan.

The family members of the children took photos with the doctors and nurses of proton radiotherapy to celebrate the successful completion of the treatment. When the little patient was seen on November 23, 2014, he had already experienced abdominal pain for half a month, and had a fever for four days. . The results of the biopsy on November 27 were considered embryonic rhabdomyosarcoma. Stage 4 chemotherapy was performed from December 1, 2014 to February 4, 2015, and surgery was performed on April 10, 2015. Postoperative pathological diagnosis was biased towards embryonic rhabdomyosarcoma.

Family members of the children took a group photo with Dr. Akio Akimoto, head of the Proton Center of the National Cancer Center of Japan

 The father of the patient soon contacted XKmed (with Kang Evergreen), contacted Ms. Bi Yanan from the International Medical Department, consulted about the itinerary to Japan and conducted a remote consultation. treatment.

It took about one month from the start of consultation to the start of treatment in Japan, including visa application. The family members of the patients took their pathological slides in China and made a pathological diagnosis again at the National Cancer Center. The result was also considered to be embryonic rhabdomyosarcoma to the greatest extent.

This little patient and his family, they obtained a medical visa on June 24, 2015, arrived in Japan on June 28, started the inspection on June 29, and completed the inspection on July 1. Professor Qiu Yuan, deputy director of the Eastern Hospital of the National Cancer Center of Japan, made a treatment plan. The treatment time is from July 14 to August 18, 2015. The total dose is: 41.4GyE, a total of 23 exposures.

On August 20, 2015, the patient’s family boarded a flight back home and successfully completed proton therapy. According to the final treatment report of the National Cancer Center, the CD of the CT before and after the patient’s irradiation has also been passed to the father of the patient.

The National Cancer Center is Japan’s most cancer treatment institution, and it is also well-known worldwide. The National Cancer Center East Hospital was established in Chiba Prefecture in 1992. Proton therapy is also one of the features here, and it has become famous because of the healing of Japanese cultural celebrities. The proton therapy system here is the first in Japan and the second medical institution in the world to begin clinical application.

Dr. Akio Akimoto, deputy director of the Eastern Hospital of the National Cancer Center and head of the radiotherapy and proton center in Japan, has extensive treatment experience as a head. By bringing Kang Evergreen to help patients who are treated in Japan, they can get the opportunity for personal treatment by Dr. Akimoto. Many Japanese cancer patients are also relatively rare.

Rhabdomyosarcoma (RMS) is a malignant tumor of interstitial origin. It is the most common type of soft tissue sarcoma in children. Its incidence is inferior to malignant fibrous histiocytoma and liposarcoma.

Although the cost of using proton therapy for pediatric patients is higher than that of photon therapy, if the medical costs of treating late adverse reactions are considered in these analyses, proton therapy will ultimately save the total treatment cost because proton therapy will reduce late adverse reactions after treatment.

Subscribe To Our Newsletter

Get updates and never miss a blog from Cancerfax

More To Explore

After amazing growth of CAR T-Cell therapy what's next
CAR T-Cell therapy

After amazing growth of CAR T-Cell therapy: what’s next?

CAR T-cell therapy has rapidly transformed cancer treatment by reprogramming a patient’s T-cells to attack cancer cells, demonstrating remarkable success in hematologic cancers. Advances in genetic engineering, regulatory support, and investment are driving further expansion. Researchers are now tackling the challenges of applying this therapy to solid tumors, aiming to enhance efficacy and accessibility, marking a new era in personalized cancer therapy and immunotherapy.

Lutetium Lu 177 dotatate is approved by USFDA for pediatric patients 12 years and older with GEP-NETS

Lutetium Lu 177 dotatate is approved by USFDA for pediatric patients 12 years and older with GEP-NETS

Lutetium Lu 177 dotatate, a groundbreaking treatment, has recently received approval from the US Food and Drug Administration (FDA) for pediatric patients, marking a significant milestone in pediatric oncology. This approval represents a beacon of hope for children battling neuroendocrine tumors (NETs), a rare but challenging form of cancer that often proves resistant to conventional therapies.

Need help? Our team is ready to assist you.

We wish a speedy recovery of your dear and near one.

Start chat
We Are Online! Chat With Us!
Scan the code

Welcome to CancerFax !

CancerFax is a pioneering platform dedicated to connecting individuals facing advanced-stage cancer with groundbreaking cell therapies like CAR T-Cell therapy, TIL therapy, and clinical trials worldwide.

Let us know what we can do for you.

1) Cancer treatment abroad?
2) CAR T-Cell therapy
3) Cancer vaccine
4) Online video consultation
5) Proton therapy